Several other brokerages also recently issued reports on HSKA. Canaccord Genuity lowered their price target on Heska from $95.00 to $75.00 and set a buy rating for the company in a report on Thursday, September 12th. ValuEngine upgraded Heska from a buy rating to a strong-buy rating in a report on Thursday, August 1st. Finally, Guggenheim began coverage on Heska in a report on Thursday, May 23rd. They issued a neutral rating for the company. One investment analyst has rated the stock with a sell rating, six have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. Heska currently has a consensus rating of Hold and an average price target of $85.25.
Shares of Heska stock opened at $72.77 on Wednesday. Heska has a 1 year low of $62.47 and a 1 year high of $114.50. The business has a 50-day moving average of $72.02 and a two-hundred day moving average of $77.39. The company has a market capitalization of $556.91 million, a P/E ratio of 72.15 and a beta of 1.07. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.93 and a quick ratio of 2.05.
Institutional investors have recently made changes to their positions in the business. Financial Gravity Wealth Inc. bought a new stake in shares of Heska in the second quarter worth about $29,000. Manchester Capital Management LLC grew its holdings in shares of Heska by 128.6% during the first quarter. Manchester Capital Management LLC now owns 400 shares of the medical research company’s stock worth $34,000 after buying an additional 225 shares in the last quarter. Aperio Group LLC bought a new position in shares of Heska during the second quarter worth about $79,000. Quantamental Technologies LLC bought a new position in shares of Heska during the second quarter worth about $120,000. Finally, BNP Paribas Arbitrage SA grew its holdings in shares of Heska by 47,400.0% during the first quarter. BNP Paribas Arbitrage SA now owns 1,425 shares of the medical research company’s stock worth $121,000 after buying an additional 1,422 shares in the last quarter. Institutional investors own 89.02% of the company’s stock.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Further Reading: How does a security become overbought?
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.